reSET-O Digital Therapeutic for Opioid Use Disorder Now Available
Sandoz and Pear Therapeutics announced the launch of reSET-O, a new digital therapeutic for patients aged ≥18 years with opioid use disorder (OUD) currently under clinician care.
All articles by DaHee Han, PharmD
FDA to Review Treatment for Jet Lag Disorder
In the Phase 3 JET8 study (N=318), patients underwent a circadian challenge of 8 hours in advance to their usual bedtime.
Prevalence of Benzodiazepine Use, Misuse Among US Adults Analyzed
Alprazolam was found to be the most commonly misused benzodiazepine.
FDA Clears Freespira Digital Therapeutic for Post-Traumatic Stress Disorder
Palo Alto Health Sciences announced that the FDA has granted clearance to Freespira, a new digital therapeutic for the treatment of PTSD.
Prescription Digital Therapeutic Approved for Opioid Use Disorder
Sandoz and Pear Therapeutics announced that the FDA has granted clearance for reSET-O, the first prescription digital therapeutic for patients with opioid use disorder.
FDA to Review Lumateperone for Treatment of Schizophrenia
Lumateperone and follow-on compounds are also being evaluated for bipolar depression, behavioral disturbance associated with dementia, sleep disturbances associated with neuropsychiatric disorders, and other neuropsychiatric conditions including major depressive disorder and autism.
Prescription Digital Therapeutic reSET Now Available for Patients With SUD
Sandoz and Pear Therapeutics announced the availability of reSET, the first prescription digital therapeutic for patients with substance use disorder.
Oral Therapy for Suicidal Bipolar Depression Gets Breakthrough Designation
NeuroRx announced that the FDA has granted Breakthrough Therapy designation to NRX-101 for the treatment of severe bipolar depression with acute suicidal ideation.
FDA Panel Votes on Postpartum Depression Treatment Zulresso
If approved, Zulresso would be the first drug approve for the treatment of postpartum depression.
FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
The 23andMe Personal Genome Service Pharmacogenetic Reports test can detect 33 variants for multiple genes, corresponding to more than 50 commonly prescribed medications and over-the-counter products.
Next post in Practice Management
